However, PROTAC technology offers potential use at low-dose for effective degradation of the target protein, making it a promising approach for targeting ASK1 and developing new treatments for diseases, such as NASH and DKD. This evidence concerns the gene MAP3K5 and metabolic dysfunction-associated steatohepatitis.